Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

A new product, a retinoic acid solution (0.3%), is available to enhance minoxidil products like Rogaine and Kirkland by converting them into a tretinoin-containing solution for improved hair loss treatment. One unit of the product is enough for a year's supply.

The user has been using topical minoxidil with tretinoin for 9 months without much regrowth and suspects finasteride is responsible for any improvement. They are inquiring about tests to determine response to topical minoxidil and seeking advice on switching to oral minoxidil, including potential side effects and monitoring requirements.

RU58841, combined with Dutasteride and topical Minoxidil, is helping users slow hair loss. Long-term users report positive results without significant side effects.

The user experienced hair loss due to a crash diet and later developed scarring hair loss. They are now on finasteride, oral minoxidil, LDN, Zyrtec, and Oztela to reduce scalp inflammation and promote hair regrowth.

Hair loss discussion includes topical latanoprost and melatonin. Users share regimens and products used for treatment.

The conversation discusses androgen receptor degraders for hair loss, highlighting their potential advantages over traditional AR blockers like RU58841 and pyrilutamide. Concerns about the safety and cost of these treatments are also mentioned.

HMI-115, a potential treatment for hair loss that has been reported to produce significant regrowth in bald areas. It is the closest thing to a cure currently available and has raised hope that it could make hair transplants obsolete.

The conversation is about using RU58841 for hair loss, with OP currently using topical finasteride. OP is seeking experiences and advice on RU58841.

The user is questioning if their hair is regrowing and considering adding tretinoin to their regimen, which includes minoxidil. They are concerned about male pattern baldness and comparing their current hairline to past photos.

The conversation discusses an interview with Dr. Tsuji about hair follicle stem cell multiplication and the financial challenges of starting human clinical trials. It also mentions the need for funding to secure a patent for a protein that promotes hair growth.

A 25-year-old male experiencing hair shedding due to testosterone use is considering topical finasteride or RU58841 for scalp treatment while continuing minoxidil for beard growth. Topical finasteride is suggested to prevent scalp thinning without affecting beard growth.

The conversation is about the effectiveness and trustworthiness of Pyrilutamide hair loss treatment sold by Hairlisciously, with concerns about product purity and a request for alternative suppliers. No specific treatments were confirmed to be used by participants.

The conversation is about finding affordable tretinoin with UK delivery options. Users discuss a finasteride, minoxidil, and tretinoin spray from e-surgery and suggest other sources like Zing meds and Skinorac.

PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.

A 35-year-old had a hair transplant with 3,153 grafts at HLC Ankara, experiencing some pain and numbness but pleased with the density and results. The procedure cost $10,000, and the user has been using finasteride for over 13 years.

The user has been using finasteride and minoxidil with tretinoin for 5 months and is questioning if they see hair regrowth. Others share their experiences and challenges with hair loss treatments, particularly the availability of medications.

RU58841 treatment for hair loss, comparing premixed solutions to powder form. Users prefer powder for cost-effectiveness and customization.

A potential treatment for alopecia involving a protein that calms hair follicles has shown promise in rats, but skepticism remains about its applicability to humans. Many users express doubt about the timeline for effective hair loss treatments, comparing it to past unfulfilled promises.

The user is considering using RU58841 and pyrilutamide for hair loss, debating between powder and topical forms, and is currently using a combination of dutasteride, finasteride, minoxidil, tretinoin, and supplements. They report no significant side effects from finasteride and dutasteride, and are seeing some hair growth, but not on the scalp.

A trichologist prescribed Biotrade Sebomax HR Anti-Hair Loss Tonic, Spectral DNC-N Nanoxidil, Hairfollic Him/Man Vitamins, and Bosley MD DHT blocking supplements instead of finasteride due to potential risks at age 21. The user questions the legitimacy of the treatment and considers seeking a second opinion.

Estrogen injections significantly improved hair growth, particularly on the crown, after stopping finasteride. Monotherapy with estrogen led to hairline improvement, but also caused sterility and potential feminization effects.

Researching the release of phase 2 trials for pyrilutamide, a potential hair loss treatment, and discussing other treatments such as Minoxidil, Finasteride, and RU58841.

A human trial of verteporfin, a potential treatment for hair loss, with some users noting potential improvements in scarring and overall healing compared to control areas.

Considering a hair transplant, using Pyrilutamide, the potential availability of CosmeRNA, and the significance of taking Minoxidil and Finasteride for long-term results.

Chronostim is a hair treatment with separate day and night formulas containing ingredients like lauric acid, glycyrrhetinic acid, and piroctone olamine. Users discuss its effectiveness for hair loss.

A 27-year-old male is experiencing a recurring pattern of hair loss after 5 months of using oral minoxidil and finasteride, despite initial success. He is considering using topical androgen receptor blockers like RU58841, pyrilutamide, or clascoterone to address potential androgen receptor hypersensitivity.

The user experienced reduced hair shedding after three months of injecting 1mg BPC-157 into the scalp, while continuing to use dutasteride and minoxidil. The injections are painful, and the user sometimes switches to injecting into the buttocks.

A hair transplant without using finasteride or similar medications may lead to unnatural results and further hair loss. Financially capable individuals are advised to stabilize hair loss with medication before considering a transplant.

The conversation discusses the differences between KB solution and PG + Ethanol solution for RU58841 in treating hair loss. It compares the effectiveness and properties of these two solutions.